Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Virology
Shuo Song et al.
Summary: This study suggests that a third booster dose of a heterologous RBD vaccine after two doses of inactivated vaccines can significantly enhance neutralizing antibody responses against various SARS-CoV-2 variants. The findings highlight the potential of heterologous vaccines in the development of next-generation COVID-19 vaccines.
Article
Immunology
Xun Wang et al.
Summary: This study found that the Omicron variant is highly resistant to neutralization by sera from convalescents or individuals vaccinated with two doses of inactivated whole-virion vaccines. However, a homologous or heterologous booster significantly increased neutralization titers. Additionally, the Omicron variant resists most monoclonal antibodies targeting distinct epitopes. These findings highlight the importance of pushing forward booster vaccinations to combat emerging SARS-CoV-2 variants.
EMERGING MICROBES & INFECTIONS
(2022)
News Item
Infectious Diseases
Sharmila Devi
LANCET INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After administering the fourth dose of BNT162b2 vaccine to individuals aged 60 years and older during the period when the omicron variant was predominant, Israel observed lower rates of confirmed SARS-CoV-2 infection and severe Covid-19 compared to those who received only three doses. The protection against severe illness remained consistent, while the protection against confirmed infection decreased over time.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Gili Regev-Yochay et al.
Summary: Health care workers in Israel received a fourth dose of mRNA vaccine during the prevalence of the omicron variant. The fourth dose boosted antibody levels but did not surpass the maximum observed after the third dose. The vaccine demonstrated an efficacy of 31 to 43% against symptomatic disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Jingyou Yu et al.
Summary: Although immunity from two doses of BNT162b2 vaccine diminishes over time, a booster dose significantly enhances the neutralizing antibodies against both the BA.1 and BA.2 variants.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Sho Iketani et al.
Summary: The identification of the Omicron variant of SARS-CoV-2 in Botswana in November 2021 sparked concern due to the spike protein alterations that could potentially evade antibodies. Further studies showed that the Omicron sublineages, BA.1+R346K and BA.2, are antigenically similar to the wild-type virus and pose similar risks to the effectiveness of current vaccines. BA.2 also demonstrated resistance to many neutralizing monoclonal antibodies, highlighting the challenges in developing effective therapeutic options.
Letter
Cell Biology
Bin Ju et al.
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Article
Multidisciplinary Sciences
Bruno Pozzetto et al.
Summary: The study found that a heterologous vaccination regimen using ChAdOx1-S-nCoV-19 and BNT162b2 can provide better protection against SARS-CoV-2 infection with stronger neutralizing activity. This approach can activate memory B cells that recognize SARS-CoV-2, making it suitable for immunocompromised individuals.
Letter
Medicine, General & Internal
Ann R. Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, Research & Experimental
Ralf Duerr et al.
Summary: The study found that breakthrough infections still occur after receiving COVID-19 mRNA vaccines, but the vaccines have high efficacy against B.1.1.7 and B.1.526 variants.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
